



PREFERENTIALLY RECOMMENDED FOR 65+ OVER STANDARD-DOSE FLU VACCINES¹

ACIP preferentially recommends adjuvanted and higher dose vaccines over standard-dose influenza vaccines for adults 65 years and older.¹

An ACIP systematic review examined **RCT and RWE data** to assess the relative benefits and harms of any adjuvanted or higher dose vaccines compared with standard-dose influenza vaccines and compared with one another in adults 65+. Evidence did not indicate superiority of any higher dose or adjuvanted vaccine over the other.²

ACIP Recommendation for 65+¹

Adults aged ≥ 65 years preferentially receive any one of the following **adjuvanted** or **higher dose** influenza vaccines[†]:

- **adjuvanted inactivated influenza vaccine**
- **high-dose inactivated influenza vaccine**
- **recombinant influenza vaccine**

If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.

For the full ACIP seasonal influenza vaccine recommendations (*Morbidity and Mortality Weekly Report—MMWR*), [click here](#).

Give your patients 65+ the Adjuvant Advantage^{†1}

FLUAD[®] (Influenza Vaccine, Adjuvanted) is the first and only adjuvanted flu vaccine designed to address a weakened immune system and strain mismatch by boosting the immune response of adults 65+ more than antigen alone.³⁻⁶ [Visit flu360.com](http://flu360.com) for more details on FLUAD.

*Analysis reviewed available data for trivalent and quadrivalent formulations.

[†]Adjuvanted or higher dose influenza vaccines include FLUAD[®], FLUZONE[®] HIGH-DOSE, and FLUBLOK[®].

[‡]Preferentially recommended by ACIP for adults 65+ over non-adjuvanted, standard-dose influenza vaccines.

ACIP=Advisory Committee on Immunization Practices; RCT=randomized controlled trial; RWE=real-world evidence

FLUAD® (Influenza Vaccine, Adjuvanted)

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

FLUAD is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in adults 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Do not administer FLUAD to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine.

WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUAD.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD. Procedures should be in place to avoid injury from fainting.

The immune response to FLUAD in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD may not protect all vaccine recipients against influenza disease.

ADVERSE REACTIONS

The most common ($\geq 10\%$) local and systemic adverse reactions in adults 65 years of age and older who received FLUAD were injection site pain (25%), injection site tenderness (21%), myalgia (15%), fatigue (13%) and headache (13%).

Other adverse events may occur.

To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

Before administration, please see the [full US Prescribing Information for FLUAD](#).

REFERENCES: 1. Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2023–24 influenza season. *MMWR Recomm Rep*. 2023;72(2):1-25. 2. Grohskopf L. Influenza vaccines for older adults: GRADE summary. February 23, 2022. Accessed June 6, 2024. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-23-24/04-influenza-grohskopf-508.pdf> 3. O'Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. *Vaccine*. 2012;30(29):4341-4348. 4. O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59® adjuvant: a phoenix that arose from the ashes. *Expert Rev Vaccines*. 2013;12(1):13-30. 5. Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. *Influenza Other Respir Viruses*. 2008;2(6):243-249. 6. FLUAD. Package insert. Seqirus Inc.

For US Healthcare Professional Use Only

flu360, FLUAD, and FLUAD QUADRIVALENT are registered trademarks of Seqirus UK Limited or its affiliates. All other trademarks are property of their respective owners. Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA ©2024 Seqirus USA Inc. July 2024 USA-FLUAD-24-0030

CSL Seqirus